| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pectins | 11 | 2023 | 27 | 5.190 |
Why?
|
| Pleura | 10 | 2024 | 244 | 5.170 |
Why?
|
| Pneumonectomy | 54 | 2023 | 1111 | 4.820 |
Why?
|
| Lung | 52 | 2024 | 9985 | 3.280 |
Why?
|
| Microcirculation | 20 | 2022 | 1273 | 2.700 |
Why?
|
| Neovascularization, Physiologic | 15 | 2023 | 1332 | 2.690 |
Why?
|
| Pulmonary Alveoli | 9 | 2017 | 651 | 1.960 |
Why?
|
| Capillaries | 8 | 2014 | 744 | 1.510 |
Why?
|
| Tropoelastin | 2 | 2023 | 28 | 1.470 |
Why?
|
| Regeneration | 11 | 2015 | 1505 | 1.440 |
Why?
|
| Neovascularization, Pathologic | 11 | 2024 | 2638 | 1.440 |
Why?
|
| Chorioallantoic Membrane | 2 | 2023 | 50 | 1.350 |
Why?
|
| Tissue Adhesives | 3 | 2020 | 173 | 1.310 |
Why?
|
| Microscopy, Electron, Scanning | 18 | 2019 | 940 | 1.260 |
Why?
|
| Lung Injury | 4 | 2023 | 424 | 1.210 |
Why?
|
| Blood Vessels | 7 | 2017 | 1112 | 1.130 |
Why?
|
| Epithelium | 4 | 2020 | 1605 | 1.060 |
Why?
|
| Microvessels | 6 | 2017 | 572 | 1.030 |
Why?
|
| Colitis | 8 | 2013 | 1229 | 1.000 |
Why?
|
| Lymphocytes | 17 | 2009 | 2610 | 0.980 |
Why?
|
| Regional Blood Flow | 10 | 2014 | 1486 | 0.980 |
Why?
|
| Glycocalyx | 3 | 2023 | 94 | 0.880 |
Why?
|
| Epithelial Cells | 5 | 2024 | 3664 | 0.870 |
Why?
|
| Sheep | 24 | 2011 | 1441 | 0.810 |
Why?
|
| Animals | 107 | 2024 | 167768 | 0.810 |
Why?
|
| Flow Cytometry | 20 | 2013 | 5864 | 0.790 |
Why?
|
| Respiratory Mechanics | 8 | 2018 | 699 | 0.780 |
Why?
|
| Colon | 6 | 2013 | 1787 | 0.770 |
Why?
|
| Stress, Mechanical | 11 | 2017 | 1664 | 0.770 |
Why?
|
| Endothelial Cells | 6 | 2022 | 3533 | 0.740 |
Why?
|
| Membranes, Artificial | 2 | 2020 | 366 | 0.730 |
Why?
|
| Corrosion Casting | 9 | 2022 | 15 | 0.710 |
Why?
|
| Citrus | 1 | 2019 | 44 | 0.680 |
Why?
|
| Hybridomas | 9 | 2009 | 442 | 0.680 |
Why?
|
| Mice | 66 | 2023 | 81101 | 0.680 |
Why?
|
| Antigens, Surface | 20 | 2002 | 1607 | 0.670 |
Why?
|
| Mice, Inbred C57BL | 27 | 2018 | 22003 | 0.660 |
Why?
|
| Biopolymers | 1 | 2020 | 184 | 0.660 |
Why?
|
| Microscopy, Video | 7 | 2014 | 242 | 0.640 |
Why?
|
| Myofibroblasts | 2 | 2019 | 207 | 0.630 |
Why?
|
| Lung Neoplasms | 39 | 2020 | 13245 | 0.620 |
Why?
|
| Mice, Inbred BALB C | 22 | 2013 | 6209 | 0.620 |
Why?
|
| Acoustics | 1 | 2019 | 242 | 0.600 |
Why?
|
| Airway Resistance | 3 | 2017 | 400 | 0.590 |
Why?
|
| Lymphoid Tissue | 2 | 2009 | 445 | 0.590 |
Why?
|
| Microscopy, Fluorescence | 7 | 2017 | 2646 | 0.590 |
Why?
|
| Polysaccharides | 2 | 2020 | 1007 | 0.560 |
Why?
|
| Acute Lung Injury | 1 | 2020 | 367 | 0.560 |
Why?
|
| Water | 2 | 2020 | 1402 | 0.560 |
Why?
|
| Pulmonary Emphysema | 10 | 2007 | 688 | 0.550 |
Why?
|
| Oxazolone | 5 | 2003 | 61 | 0.550 |
Why?
|
| Microspheres | 5 | 2009 | 787 | 0.540 |
Why?
|
| Endothelium, Vascular | 14 | 2020 | 4429 | 0.530 |
Why?
|
| Parabiosis | 2 | 2013 | 64 | 0.500 |
Why?
|
| Blood Circulation | 2 | 2009 | 249 | 0.500 |
Why?
|
| Pulmonary Circulation | 4 | 2022 | 743 | 0.500 |
Why?
|
| Lung Transplantation | 11 | 2017 | 1305 | 0.490 |
Why?
|
| Lymph | 4 | 2002 | 77 | 0.490 |
Why?
|
| Ischemia | 2 | 2022 | 1863 | 0.480 |
Why?
|
| Antibodies, Monoclonal | 35 | 2011 | 9160 | 0.480 |
Why?
|
| Lung Compliance | 2 | 2012 | 201 | 0.470 |
Why?
|
| T-Lymphocytes, Cytotoxic | 16 | 1996 | 1765 | 0.470 |
Why?
|
| Pneumothorax | 1 | 2017 | 379 | 0.460 |
Why?
|
| Melitten | 2 | 2005 | 13 | 0.460 |
Why?
|
| Microscopy, Electron, Transmission | 5 | 2020 | 695 | 0.460 |
Why?
|
| Proteoglycans | 1 | 2017 | 801 | 0.460 |
Why?
|
| Skin | 9 | 2011 | 4464 | 0.460 |
Why?
|
| Elastin | 1 | 2015 | 300 | 0.450 |
Why?
|
| Intestinal Mucosa | 7 | 2013 | 3020 | 0.450 |
Why?
|
| Fluorescent Dyes | 7 | 2010 | 1897 | 0.440 |
Why?
|
| Butyrates | 4 | 2006 | 168 | 0.440 |
Why?
|
| Connective Tissue | 1 | 2015 | 416 | 0.440 |
Why?
|
| Phrenic Nerve | 1 | 2013 | 79 | 0.440 |
Why?
|
| Respiratory Paralysis | 1 | 2013 | 32 | 0.440 |
Why?
|
| Thoracoscopy | 11 | 2005 | 176 | 0.430 |
Why?
|
| Computational Biology | 4 | 2009 | 3502 | 0.430 |
Why?
|
| Chick Embryo | 2 | 2014 | 981 | 0.420 |
Why?
|
| Cell Shape | 2 | 2024 | 371 | 0.420 |
Why?
|
| Thoracic Neoplasms | 4 | 2017 | 266 | 0.420 |
Why?
|
| Macrophages, Alveolar | 2 | 2012 | 409 | 0.420 |
Why?
|
| Lung Volume Measurements | 8 | 2013 | 375 | 0.410 |
Why?
|
| Green Fluorescent Proteins | 3 | 2013 | 2057 | 0.400 |
Why?
|
| Bronchi | 4 | 2022 | 848 | 0.400 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2017 | 730 | 0.400 |
Why?
|
| Diaphragm | 2 | 2013 | 351 | 0.390 |
Why?
|
| Cell Movement | 8 | 2013 | 5201 | 0.390 |
Why?
|
| Cell Membrane Permeability | 2 | 2005 | 575 | 0.390 |
Why?
|
| Lymphatic System | 3 | 2002 | 254 | 0.390 |
Why?
|
| Extraembryonic Membranes | 1 | 2011 | 38 | 0.380 |
Why?
|
| Cytotoxicity, Immunologic | 13 | 1990 | 1351 | 0.380 |
Why?
|
| Cell Adhesion | 13 | 2019 | 3090 | 0.370 |
Why?
|
| Thoracic Wall | 4 | 2012 | 199 | 0.370 |
Why?
|
| Arginine | 4 | 2006 | 933 | 0.350 |
Why?
|
| Blood Flow Velocity | 3 | 2009 | 1370 | 0.350 |
Why?
|
| Adjuvants, Immunologic | 5 | 2003 | 1038 | 0.350 |
Why?
|
| Adaptation, Physiological | 3 | 2012 | 1295 | 0.350 |
Why?
|
| Video Recording | 5 | 2007 | 954 | 0.350 |
Why?
|
| Erythema | 3 | 2006 | 262 | 0.340 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 18 | 2020 | 5246 | 0.340 |
Why?
|
| Phase Transition | 2 | 2019 | 71 | 0.340 |
Why?
|
| Colitis, Lymphocytic | 1 | 2009 | 23 | 0.330 |
Why?
|
| Antigens, CD34 | 1 | 2011 | 653 | 0.330 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2014 | 530 | 0.330 |
Why?
|
| Cluster Analysis | 6 | 2011 | 2697 | 0.320 |
Why?
|
| Pleural Neoplasms | 9 | 2007 | 609 | 0.320 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 15 | 1996 | 377 | 0.320 |
Why?
|
| Nanoparticles | 4 | 2010 | 1940 | 0.320 |
Why?
|
| Monocytes | 8 | 2003 | 2570 | 0.310 |
Why?
|
| Lung Diseases, Interstitial | 3 | 2022 | 909 | 0.310 |
Why?
|
| Immunoglobulins | 2 | 2006 | 859 | 0.310 |
Why?
|
| Ganciclovir | 4 | 2006 | 252 | 0.310 |
Why?
|
| Image Processing, Computer-Assisted | 8 | 2015 | 8945 | 0.300 |
Why?
|
| Dimethylpolysiloxanes | 1 | 2008 | 142 | 0.300 |
Why?
|
| Epstein-Barr Virus Infections | 4 | 2006 | 608 | 0.300 |
Why?
|
| Osteomalacia | 1 | 2007 | 56 | 0.290 |
Why?
|
| Herpesvirus 4, Human | 4 | 2001 | 1075 | 0.290 |
Why?
|
| Respiration | 4 | 2022 | 1654 | 0.280 |
Why?
|
| X-Ray Microtomography | 4 | 2019 | 443 | 0.280 |
Why?
|
| Tracheal Neoplasms | 1 | 2007 | 123 | 0.280 |
Why?
|
| Mucous Membrane | 1 | 2010 | 656 | 0.270 |
Why?
|
| Cell Separation | 5 | 2016 | 1720 | 0.270 |
Why?
|
| Bronchial Arteries | 2 | 2022 | 21 | 0.270 |
Why?
|
| Microscopy, Confocal | 3 | 2009 | 1969 | 0.270 |
Why?
|
| Calcium | 1 | 2019 | 5721 | 0.270 |
Why?
|
| Biological Clocks | 1 | 2009 | 316 | 0.270 |
Why?
|
| Peptide Mapping | 1 | 2006 | 262 | 0.260 |
Why?
|
| Platelet Aggregation | 1 | 2009 | 773 | 0.260 |
Why?
|
| Male | 100 | 2023 | 358747 | 0.260 |
Why?
|
| Ear, External | 1 | 2006 | 164 | 0.260 |
Why?
|
| Bees | 1 | 2005 | 45 | 0.260 |
Why?
|
| Models, Biological | 6 | 2024 | 9460 | 0.260 |
Why?
|
| Thoracic Surgical Procedures | 3 | 2017 | 348 | 0.260 |
Why?
|
| Cell Adhesion Molecules | 6 | 2001 | 1600 | 0.260 |
Why?
|
| Mesothelioma | 8 | 2004 | 807 | 0.250 |
Why?
|
| Animals, Newborn | 2 | 2024 | 2672 | 0.250 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2007 | 262 | 0.250 |
Why?
|
| Motion | 1 | 2008 | 779 | 0.240 |
Why?
|
| Carboplatin | 1 | 2007 | 788 | 0.240 |
Why?
|
| Glycoconjugates | 2 | 1995 | 88 | 0.240 |
Why?
|
| Immunophenotyping | 3 | 2006 | 1871 | 0.240 |
Why?
|
| Neoplasm Staging | 22 | 2020 | 11152 | 0.230 |
Why?
|
| Extracellular Matrix | 2 | 2023 | 1723 | 0.230 |
Why?
|
| Thoracic Diseases | 1 | 2005 | 99 | 0.230 |
Why?
|
| Positive-Pressure Respiration | 3 | 2017 | 636 | 0.210 |
Why?
|
| Abdominal Cavity | 1 | 2023 | 34 | 0.210 |
Why?
|
| Time Factors | 18 | 2016 | 39872 | 0.210 |
Why?
|
| Inflammation | 9 | 2022 | 10718 | 0.210 |
Why?
|
| Humans | 160 | 2024 | 758406 | 0.210 |
Why?
|
| Respiratory Function Tests | 8 | 2017 | 1680 | 0.210 |
Why?
|
| Sarcoidosis | 2 | 2000 | 520 | 0.210 |
Why?
|
| Finite Element Analysis | 3 | 2014 | 428 | 0.200 |
Why?
|
| Disease Models, Animal | 11 | 2020 | 18119 | 0.200 |
Why?
|
| Thorax | 3 | 2022 | 553 | 0.200 |
Why?
|
| Neoadjuvant Therapy | 6 | 2020 | 2821 | 0.200 |
Why?
|
| Cell Proliferation | 5 | 2017 | 10416 | 0.200 |
Why?
|
| Trinitrobenzenesulfonic Acid | 3 | 2013 | 64 | 0.200 |
Why?
|
| Lymphocyte Activation | 10 | 1996 | 5490 | 0.200 |
Why?
|
| Thymidine Kinase | 2 | 2001 | 286 | 0.190 |
Why?
|
| Gramicidin | 1 | 2001 | 12 | 0.190 |
Why?
|
| Stethoscopes | 1 | 2021 | 30 | 0.190 |
Why?
|
| Fibroblast Growth Factors | 1 | 2007 | 867 | 0.190 |
Why?
|
| Thymus Gland | 2 | 2009 | 1244 | 0.190 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 2 | 2022 | 447 | 0.190 |
Why?
|
| Blood Platelets | 2 | 2009 | 2475 | 0.190 |
Why?
|
| Oxazoles | 1 | 2002 | 199 | 0.190 |
Why?
|
| T-Lymphocytes | 9 | 2012 | 10171 | 0.190 |
Why?
|
| Models, Anatomic | 2 | 2017 | 681 | 0.190 |
Why?
|
| Oxygen | 3 | 2011 | 4191 | 0.190 |
Why?
|
| Fixatives | 1 | 2001 | 91 | 0.190 |
Why?
|
| Chickens | 1 | 2023 | 860 | 0.190 |
Why?
|
| Dermatitis, Contact | 1 | 2001 | 133 | 0.190 |
Why?
|
| Mediastinoscopy | 2 | 1997 | 29 | 0.190 |
Why?
|
| Computer Simulation | 4 | 2024 | 6201 | 0.190 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2020 | 9273 | 0.190 |
Why?
|
| Gels | 2 | 2020 | 419 | 0.190 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2007 | 867 | 0.180 |
Why?
|
| Computer Graphics | 1 | 2003 | 340 | 0.180 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2001 | 88 | 0.180 |
Why?
|
| Hypertension, Pulmonary | 3 | 2017 | 1564 | 0.180 |
Why?
|
| Nanotechnology | 1 | 2006 | 707 | 0.180 |
Why?
|
| Cytotoxins | 1 | 2001 | 153 | 0.180 |
Why?
|
| Myelopoiesis | 1 | 2021 | 134 | 0.180 |
Why?
|
| Dextran Sulfate | 3 | 2013 | 255 | 0.180 |
Why?
|
| Lymphocyte Transfusion | 1 | 2001 | 232 | 0.180 |
Why?
|
| Fibrin Tissue Adhesive | 1 | 2020 | 86 | 0.180 |
Why?
|
| Respiratory Rate | 1 | 2021 | 175 | 0.180 |
Why?
|
| Microvilli | 1 | 2020 | 233 | 0.180 |
Why?
|
| Phantoms, Imaging | 1 | 2009 | 2509 | 0.180 |
Why?
|
| Multiple Trauma | 1 | 2023 | 369 | 0.180 |
Why?
|
| Idiopathic Interstitial Pneumonias | 1 | 2020 | 24 | 0.170 |
Why?
|
| Rats | 5 | 2024 | 23679 | 0.170 |
Why?
|
| Aldehydes | 1 | 2001 | 170 | 0.170 |
Why?
|
| Surgical Stapling | 1 | 2020 | 98 | 0.170 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2003 | 663 | 0.170 |
Why?
|
| Pneumonia, Viral | 4 | 2022 | 3196 | 0.170 |
Why?
|
| Glass | 1 | 2020 | 115 | 0.170 |
Why?
|
| Thoracotomy | 6 | 1997 | 362 | 0.170 |
Why?
|
| Gene Expression Regulation, Viral | 2 | 2001 | 438 | 0.170 |
Why?
|
| Lymph Nodes | 9 | 2009 | 3485 | 0.170 |
Why?
|
| Abdominal Injuries | 1 | 2023 | 359 | 0.170 |
Why?
|
| Preoperative Care | 3 | 2007 | 2249 | 0.170 |
Why?
|
| Cattle | 3 | 2023 | 3845 | 0.170 |
Why?
|
| Histocompatibility Testing | 1 | 2001 | 717 | 0.170 |
Why?
|
| Vitrification | 1 | 2019 | 51 | 0.170 |
Why?
|
| Coloring Agents | 3 | 2009 | 560 | 0.160 |
Why?
|
| Drug Eruptions | 1 | 2002 | 335 | 0.160 |
Why?
|
| Sus scrofa | 1 | 2020 | 428 | 0.160 |
Why?
|
| Organogenesis | 2 | 2017 | 215 | 0.160 |
Why?
|
| Patient Selection | 4 | 2007 | 4244 | 0.160 |
Why?
|
| Extracellular Fluid | 2 | 2017 | 165 | 0.160 |
Why?
|
| Ear | 4 | 2007 | 172 | 0.160 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 3076 | 0.160 |
Why?
|
| Stem Cells | 1 | 2011 | 3521 | 0.160 |
Why?
|
| Chest Tubes | 2 | 2023 | 152 | 0.150 |
Why?
|
| Air Pressure | 1 | 2018 | 74 | 0.150 |
Why?
|
| Phenotype | 9 | 2017 | 16534 | 0.150 |
Why?
|
| Diffusion | 1 | 2020 | 813 | 0.150 |
Why?
|
| Synchrotrons | 2 | 2015 | 39 | 0.150 |
Why?
|
| Combined Modality Therapy | 18 | 2020 | 8530 | 0.150 |
Why?
|
| Endothelium | 3 | 2000 | 764 | 0.150 |
Why?
|
| Hydrostatic Pressure | 1 | 2017 | 95 | 0.150 |
Why?
|
| Antigens | 2 | 2001 | 1445 | 0.150 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2001 | 533 | 0.150 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 5 | 2003 | 886 | 0.150 |
Why?
|
| Transcription, Genetic | 5 | 2016 | 7590 | 0.150 |
Why?
|
| Sarcoma | 4 | 2017 | 1785 | 0.140 |
Why?
|
| Imaging, Three-Dimensional | 5 | 2017 | 4048 | 0.140 |
Why?
|
| Survival Rate | 19 | 2020 | 12721 | 0.140 |
Why?
|
| Dyspnea | 1 | 2005 | 1344 | 0.140 |
Why?
|
| Carbocyanines | 2 | 2009 | 175 | 0.140 |
Why?
|
| Haptens | 2 | 2007 | 163 | 0.140 |
Why?
|
| Organ Size | 2 | 2012 | 2252 | 0.140 |
Why?
|
| Immunoglobulin Isotypes | 2 | 1994 | 158 | 0.140 |
Why?
|
| Pneumonia | 2 | 2017 | 2129 | 0.140 |
Why?
|
| Viral Nonstructural Proteins | 1 | 1998 | 223 | 0.140 |
Why?
|
| Lymphoma, Non-Hodgkin | 3 | 2001 | 1373 | 0.140 |
Why?
|
| Lymphoma, Large-Cell, Immunoblastic | 1 | 1996 | 25 | 0.140 |
Why?
|
| Thrombosis | 2 | 2021 | 2929 | 0.140 |
Why?
|
| Image Cytometry | 1 | 2016 | 53 | 0.140 |
Why?
|
| Tumor Cells, Cultured | 10 | 2001 | 6127 | 0.130 |
Why?
|
| HLA Antigens | 8 | 1995 | 1368 | 0.130 |
Why?
|
| Algorithms | 8 | 2016 | 13961 | 0.130 |
Why?
|
| Tomography | 2 | 2015 | 411 | 0.130 |
Why?
|
| Respiration, Artificial | 3 | 2017 | 2618 | 0.130 |
Why?
|
| Lectins | 2 | 1995 | 484 | 0.130 |
Why?
|
| Models, Cardiovascular | 2 | 2014 | 972 | 0.130 |
Why?
|
| L-Selectin | 1 | 1996 | 209 | 0.130 |
Why?
|
| Surface Tension | 1 | 2015 | 43 | 0.130 |
Why?
|
| Fluoroimmunoassay | 1 | 1995 | 30 | 0.130 |
Why?
|
| Mice, Transgenic | 3 | 2013 | 9518 | 0.130 |
Why?
|
| Cornea | 1 | 2023 | 1326 | 0.130 |
Why?
|
| Staining and Labeling | 2 | 2010 | 1083 | 0.120 |
Why?
|
| Cell Differentiation | 2 | 2016 | 11471 | 0.120 |
Why?
|
| Myocarditis | 1 | 2022 | 766 | 0.120 |
Why?
|
| Rats, Wistar | 2 | 2017 | 1844 | 0.120 |
Why?
|
| Chemokines | 2 | 2009 | 961 | 0.120 |
Why?
|
| Endothelins | 1 | 1995 | 127 | 0.120 |
Why?
|
| Cell Fusion | 2 | 2009 | 293 | 0.120 |
Why?
|
| Thoracic Surgery | 3 | 1996 | 722 | 0.120 |
Why?
|
| Polymerase Chain Reaction | 2 | 2016 | 6068 | 0.120 |
Why?
|
| Telangiectasia, Hereditary Hemorrhagic | 1 | 2017 | 141 | 0.120 |
Why?
|
| Situs Inversus | 1 | 1994 | 63 | 0.120 |
Why?
|
| Membrane Glycoproteins | 2 | 2020 | 3705 | 0.120 |
Why?
|
| o-Phthalaldehyde | 1 | 1994 | 15 | 0.120 |
Why?
|
| Female | 77 | 2020 | 390323 | 0.120 |
Why?
|
| Cell Count | 3 | 2012 | 1835 | 0.120 |
Why?
|
| Total Lung Capacity | 3 | 2011 | 149 | 0.120 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2016 | 320 | 0.120 |
Why?
|
| Carcinoma, Bronchogenic | 1 | 1994 | 86 | 0.120 |
Why?
|
| Indoles | 2 | 2017 | 1828 | 0.110 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 4 | 1989 | 899 | 0.110 |
Why?
|
| Cell Membrane | 4 | 2003 | 3680 | 0.110 |
Why?
|
| Gene Expression Regulation | 4 | 2013 | 11892 | 0.110 |
Why?
|
| Cells, Cultured | 14 | 2006 | 18940 | 0.110 |
Why?
|
| Cell Aggregation | 3 | 1995 | 239 | 0.110 |
Why?
|
| Phosphines | 1 | 2013 | 18 | 0.110 |
Why?
|
| Indicators and Reagents | 1 | 1994 | 460 | 0.110 |
Why?
|
| Esophageal Neoplasms | 3 | 2016 | 1648 | 0.110 |
Why?
|
| Surgical Staplers | 2 | 1997 | 34 | 0.110 |
Why?
|
| Postoperative Complications | 12 | 2023 | 15637 | 0.110 |
Why?
|
| Liver | 3 | 2020 | 7502 | 0.110 |
Why?
|
| Adult | 59 | 2022 | 219935 | 0.110 |
Why?
|
| Killer Cells, Natural | 5 | 1995 | 2201 | 0.110 |
Why?
|
| Middle Aged | 64 | 2022 | 219568 | 0.110 |
Why?
|
| Thoracostomy | 1 | 2013 | 74 | 0.110 |
Why?
|
| Electrophoresis | 1 | 1993 | 234 | 0.110 |
Why?
|
| Cystic Adenomatoid Malformation of Lung, Congenital | 1 | 1992 | 41 | 0.100 |
Why?
|
| Immunity, Cellular | 2 | 1990 | 1557 | 0.100 |
Why?
|
| Aged | 58 | 2022 | 168218 | 0.100 |
Why?
|
| Cefazolin | 1 | 2013 | 94 | 0.100 |
Why?
|
| Antiviral Agents | 3 | 2001 | 3056 | 0.100 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2024 | 8143 | 0.100 |
Why?
|
| Body Patterning | 1 | 2017 | 632 | 0.100 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 1995 | 617 | 0.100 |
Why?
|
| Rheology | 2 | 2008 | 348 | 0.100 |
Why?
|
| Bronchoscopy | 4 | 2005 | 910 | 0.100 |
Why?
|
| Cell Size | 2 | 2005 | 623 | 0.100 |
Why?
|
| Adenocarcinoma | 5 | 2017 | 6313 | 0.100 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2012 | 129 | 0.100 |
Why?
|
| Eosine Yellowish-(YS) | 2 | 2002 | 69 | 0.100 |
Why?
|
| Leukocytes | 3 | 2013 | 2025 | 0.100 |
Why?
|
| Pandemics | 3 | 2020 | 8611 | 0.100 |
Why?
|
| Emphysema | 2 | 2007 | 240 | 0.100 |
Why?
|
| Biotin | 1 | 1993 | 253 | 0.100 |
Why?
|
| Electric Conductivity | 1 | 2012 | 405 | 0.100 |
Why?
|
| Pattern Recognition, Automated | 2 | 2009 | 994 | 0.100 |
Why?
|
| Statistical Distributions | 2 | 2002 | 63 | 0.100 |
Why?
|
| Cell Line | 16 | 2001 | 15591 | 0.100 |
Why?
|
| Apoptosis | 2 | 2005 | 9468 | 0.100 |
Why?
|
| Genes, MHC Class II | 1 | 2012 | 451 | 0.100 |
Why?
|
| Information Theory | 2 | 2002 | 49 | 0.090 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2017 | 500 | 0.090 |
Why?
|
| Fluoresceins | 3 | 2001 | 234 | 0.090 |
Why?
|
| Mediastinal Neoplasms | 1 | 1994 | 402 | 0.090 |
Why?
|
| Palliative Care | 2 | 2005 | 3570 | 0.090 |
Why?
|
| Blood Cells | 1 | 2013 | 305 | 0.090 |
Why?
|
| Fluorescent Antibody Technique | 6 | 2003 | 2470 | 0.090 |
Why?
|
| Tensile Strength | 2 | 2011 | 330 | 0.090 |
Why?
|
| Carcinoma, Small Cell | 1 | 1993 | 416 | 0.090 |
Why?
|
| B-Lymphocytes | 6 | 2001 | 4738 | 0.090 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2013 | 748 | 0.090 |
Why?
|
| Histocompatibility Antigens Class I | 3 | 1996 | 1355 | 0.090 |
Why?
|
| Elasticity | 1 | 2012 | 652 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 8 | 2022 | 20500 | 0.090 |
Why?
|
| Interleukin-1beta | 2 | 2021 | 996 | 0.090 |
Why?
|
| Cancer Vaccines | 3 | 2003 | 1046 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 9 | 2016 | 11709 | 0.090 |
Why?
|
| Pericardial Effusion | 2 | 2005 | 247 | 0.080 |
Why?
|
| Periodicity | 1 | 2011 | 348 | 0.080 |
Why?
|
| Dendritic Cells | 2 | 2000 | 2723 | 0.080 |
Why?
|
| Antibiotic Prophylaxis | 2 | 2013 | 642 | 0.080 |
Why?
|
| Intussusception | 1 | 2010 | 115 | 0.080 |
Why?
|
| Actins | 1 | 2016 | 2049 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2001 | 8506 | 0.080 |
Why?
|
| Peptides | 1 | 2001 | 4341 | 0.080 |
Why?
|
| Leiomyosarcoma | 1 | 1993 | 424 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2012 | 557 | 0.080 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1998 | 1547 | 0.080 |
Why?
|
| Cell Cycle | 2 | 2011 | 2930 | 0.080 |
Why?
|
| Shear Strength | 1 | 2009 | 160 | 0.080 |
Why?
|
| Tidal Volume | 1 | 2011 | 487 | 0.080 |
Why?
|
| Deltaretrovirus Infections | 1 | 1988 | 25 | 0.080 |
Why?
|
| Antigens, Differentiation | 2 | 1988 | 911 | 0.080 |
Why?
|
| Aspergillosis | 2 | 2003 | 243 | 0.080 |
Why?
|
| Negative-Pressure Wound Therapy | 1 | 2011 | 153 | 0.080 |
Why?
|
| Lung Diseases, Obstructive | 2 | 2001 | 308 | 0.080 |
Why?
|
| Postoperative Period | 2 | 2012 | 1812 | 0.080 |
Why?
|
| Prognosis | 12 | 2017 | 29557 | 0.080 |
Why?
|
| Deltaretrovirus | 1 | 1988 | 161 | 0.080 |
Why?
|
| Forced Expiratory Volume | 6 | 2005 | 1806 | 0.080 |
Why?
|
| Solitary Pulmonary Nodule | 2 | 2004 | 270 | 0.080 |
Why?
|
| Epidermis | 1 | 2011 | 528 | 0.080 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2013 | 1446 | 0.080 |
Why?
|
| Lymphoma | 4 | 2006 | 1896 | 0.080 |
Why?
|
| Ethics, Medical | 1 | 1994 | 783 | 0.080 |
Why?
|
| Survival Analysis | 11 | 2009 | 10112 | 0.080 |
Why?
|
| Abdominal Neoplasms | 2 | 1997 | 286 | 0.080 |
Why?
|
| Membrane Proteins | 5 | 2021 | 7843 | 0.080 |
Why?
|
| Silicon Dioxide | 1 | 2009 | 216 | 0.070 |
Why?
|
| Myocardium | 1 | 2020 | 4690 | 0.070 |
Why?
|
| Polystyrenes | 1 | 2007 | 104 | 0.070 |
Why?
|
| Picrates | 1 | 2007 | 13 | 0.070 |
Why?
|
| Hemorheology | 1 | 2007 | 144 | 0.070 |
Why?
|
| Platelet Adhesiveness | 1 | 2007 | 153 | 0.070 |
Why?
|
| Acute Disease | 2 | 2009 | 7225 | 0.070 |
Why?
|
| Picryl Chloride | 1 | 2006 | 9 | 0.070 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1988 | 818 | 0.070 |
Why?
|
| Neoplasms, Fibrous Tissue | 1 | 2007 | 20 | 0.070 |
Why?
|
| Fluorescence | 2 | 2007 | 749 | 0.070 |
Why?
|
| Pleural Effusion | 2 | 2005 | 342 | 0.070 |
Why?
|
| Epitopes | 5 | 1989 | 2502 | 0.070 |
Why?
|
| Software | 4 | 2011 | 4415 | 0.070 |
Why?
|
| Receptors, Immunologic | 2 | 1990 | 1411 | 0.070 |
Why?
|
| Esophageal Perforation | 1 | 2007 | 65 | 0.070 |
Why?
|
| Hydrogen Peroxide | 1 | 1990 | 728 | 0.070 |
Why?
|
| Leukemia, Myeloid | 2 | 1987 | 695 | 0.070 |
Why?
|
| Suture Techniques | 1 | 1992 | 788 | 0.070 |
Why?
|
| Pulsatile Flow | 1 | 2008 | 320 | 0.070 |
Why?
|
| Intubation | 1 | 2007 | 139 | 0.070 |
Why?
|
| Leukemia, Lymphoid | 1 | 1987 | 310 | 0.070 |
Why?
|
| Erythrocytes | 2 | 2006 | 2413 | 0.070 |
Why?
|
| Venules | 1 | 2006 | 164 | 0.070 |
Why?
|
| Matrix Metalloproteinases | 1 | 2009 | 392 | 0.070 |
Why?
|
| Fuzzy Logic | 1 | 2006 | 57 | 0.070 |
Why?
|
| Radiotherapy, Adjuvant | 5 | 2009 | 1791 | 0.070 |
Why?
|
| Tissue Expansion | 1 | 2007 | 160 | 0.070 |
Why?
|
| Nonlinear Dynamics | 1 | 2009 | 493 | 0.070 |
Why?
|
| Aged, 80 and over | 20 | 2020 | 58683 | 0.070 |
Why?
|
| Calibration | 1 | 2009 | 814 | 0.070 |
Why?
|
| Splenomegaly | 1 | 1987 | 189 | 0.070 |
Why?
|
| Sialoglycoproteins | 1 | 1987 | 315 | 0.070 |
Why?
|
| Precancerous Conditions | 2 | 2004 | 977 | 0.070 |
Why?
|
| Transfection | 5 | 1990 | 5779 | 0.070 |
Why?
|
| Spleen | 2 | 2009 | 2296 | 0.070 |
Why?
|
| Arterioles | 1 | 2006 | 250 | 0.060 |
Why?
|
| Programming Languages | 1 | 2006 | 128 | 0.060 |
Why?
|
| Antineoplastic Agents | 4 | 2006 | 13591 | 0.060 |
Why?
|
| Lymphokines | 1 | 1988 | 926 | 0.060 |
Why?
|
| Kidney Tubular Necrosis, Acute | 1 | 1985 | 65 | 0.060 |
Why?
|
| Single-Cell Analysis | 1 | 2016 | 2379 | 0.060 |
Why?
|
| Synovial Membrane | 1 | 1988 | 524 | 0.060 |
Why?
|
| Donor Selection | 1 | 2007 | 227 | 0.060 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2016 | 3602 | 0.060 |
Why?
|
| Macrophage Activation | 1 | 1988 | 552 | 0.060 |
Why?
|
| Retrospective Studies | 19 | 2020 | 80168 | 0.060 |
Why?
|
| Transcriptional Activation | 1 | 2011 | 1752 | 0.060 |
Why?
|
| Splenectomy | 1 | 1987 | 391 | 0.060 |
Why?
|
| Postoperative Care | 3 | 2013 | 1471 | 0.060 |
Why?
|
| Biophysics | 1 | 2006 | 380 | 0.060 |
Why?
|
| RNA, Messenger | 5 | 2011 | 12759 | 0.060 |
Why?
|
| Receptors, Antigen, T-Cell | 4 | 1989 | 2532 | 0.060 |
Why?
|
| Membranes | 2 | 1995 | 165 | 0.060 |
Why?
|
| Paracentesis | 1 | 2005 | 98 | 0.060 |
Why?
|
| Hybrid Cells | 2 | 2000 | 422 | 0.060 |
Why?
|
| Infusions, Parenteral | 1 | 1984 | 398 | 0.060 |
Why?
|
| Infusions, Intra-Arterial | 1 | 1984 | 221 | 0.060 |
Why?
|
| Gene Expression Profiling | 2 | 2011 | 9404 | 0.060 |
Why?
|
| Spirometry | 3 | 2021 | 923 | 0.060 |
Why?
|
| Immunohistochemistry | 5 | 2011 | 11070 | 0.060 |
Why?
|
| Heart | 1 | 2017 | 4382 | 0.060 |
Why?
|
| Pulmonary Embolism | 1 | 2017 | 2540 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 6 | 2009 | 3527 | 0.060 |
Why?
|
| Behavior, Animal | 1 | 2012 | 1866 | 0.060 |
Why?
|
| Surgical Wound Infection | 1 | 2013 | 1526 | 0.060 |
Why?
|
| Histocytochemistry | 2 | 1995 | 700 | 0.060 |
Why?
|
| Gene Expression | 2 | 2012 | 7583 | 0.050 |
Why?
|
| Receptor, Insulin | 1 | 2007 | 833 | 0.050 |
Why?
|
| Hematoxylin | 1 | 2002 | 60 | 0.050 |
Why?
|
| Stimulation, Chemical | 1 | 2002 | 306 | 0.050 |
Why?
|
| Cytotoxicity Tests, Immunologic | 3 | 1988 | 321 | 0.050 |
Why?
|
| Swine | 2 | 2023 | 5892 | 0.050 |
Why?
|
| Gene Regulatory Networks | 1 | 2011 | 1740 | 0.050 |
Why?
|
| Follow-Up Studies | 10 | 2020 | 39059 | 0.050 |
Why?
|
| Arteriovenous Anastomosis | 1 | 2022 | 14 | 0.050 |
Why?
|
| Transplantation Immunology | 2 | 2001 | 532 | 0.050 |
Why?
|
| Lung Diseases, Fungal | 1 | 2003 | 126 | 0.050 |
Why?
|
| Gastrostomy | 2 | 2001 | 321 | 0.050 |
Why?
|
| Microscopy, Phase-Contrast | 1 | 2022 | 110 | 0.050 |
Why?
|
| Lymphatic Metastasis | 5 | 2009 | 2943 | 0.050 |
Why?
|
| HLA-A2 Antigen | 5 | 1990 | 211 | 0.050 |
Why?
|
| Blotting, Western | 3 | 2011 | 5031 | 0.050 |
Why?
|
| Interferon-gamma | 2 | 1990 | 3156 | 0.050 |
Why?
|
| Neurofibroma | 1 | 1982 | 94 | 0.050 |
Why?
|
| Sensitivity and Specificity | 6 | 2011 | 14641 | 0.050 |
Why?
|
| Enzyme Induction | 2 | 2001 | 451 | 0.050 |
Why?
|
| Hamartoma | 2 | 1995 | 235 | 0.050 |
Why?
|
| Trypan Blue | 1 | 2001 | 22 | 0.050 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2007 | 575 | 0.050 |
Why?
|
| Injections, Intradermal | 1 | 2001 | 116 | 0.050 |
Why?
|
| Mesoderm | 4 | 1995 | 672 | 0.050 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 1995 | 1743 | 0.050 |
Why?
|
| Forced Expiratory Flow Rates | 1 | 2001 | 74 | 0.050 |
Why?
|
| Inflammation Mediators | 1 | 2010 | 1878 | 0.050 |
Why?
|
| Cell Communication | 6 | 1988 | 1651 | 0.050 |
Why?
|
| Bronchiolitis Obliterans | 2 | 2000 | 213 | 0.050 |
Why?
|
| Clone Cells | 4 | 1990 | 1660 | 0.050 |
Why?
|
| Binding, Competitive | 4 | 1986 | 1141 | 0.050 |
Why?
|
| Thigh | 1 | 1982 | 240 | 0.050 |
Why?
|
| Magnetics | 2 | 1995 | 600 | 0.050 |
Why?
|
| Rhodamines | 1 | 2001 | 178 | 0.050 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2002 | 410 | 0.050 |
Why?
|
| Esophagectomy | 2 | 2001 | 466 | 0.040 |
Why?
|
| Haplorhini | 2 | 1995 | 529 | 0.040 |
Why?
|
| Doxorubicin | 3 | 1998 | 2209 | 0.040 |
Why?
|
| Antigens, Neoplasm | 1 | 1988 | 1997 | 0.040 |
Why?
|
| Mediastinum | 3 | 2001 | 266 | 0.040 |
Why?
|
| Antigens, CD | 2 | 1990 | 3997 | 0.040 |
Why?
|
| Frozen Sections | 1 | 2001 | 153 | 0.040 |
Why?
|
| Mice, Inbred AKR | 1 | 2000 | 104 | 0.040 |
Why?
|
| Weight Loss | 1 | 2012 | 2671 | 0.040 |
Why?
|
| Jugular Veins | 1 | 2001 | 210 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2021 | 3480 | 0.040 |
Why?
|
| Treatment Outcome | 18 | 2009 | 64378 | 0.040 |
Why?
|
| Esophageal Stenosis | 1 | 2001 | 192 | 0.040 |
Why?
|
| Tissue Fixation | 1 | 2001 | 241 | 0.040 |
Why?
|
| Anesthesia | 1 | 2011 | 1582 | 0.040 |
Why?
|
| Monitoring, Ambulatory | 1 | 2003 | 352 | 0.040 |
Why?
|
| Bone Marrow Cells | 2 | 2003 | 2414 | 0.040 |
Why?
|
| Wound Healing | 1 | 2011 | 2783 | 0.040 |
Why?
|
| Stochastic Processes | 1 | 2001 | 354 | 0.040 |
Why?
|
| Formaldehyde | 1 | 2001 | 358 | 0.040 |
Why?
|
| Rats, Inbred Lew | 1 | 2001 | 1154 | 0.040 |
Why?
|
| Plasmacytoma | 1 | 2000 | 171 | 0.040 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 1986 | 936 | 0.040 |
Why?
|
| Lung Diseases | 4 | 1998 | 1910 | 0.040 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2021 | 418 | 0.040 |
Why?
|
| Colonoscopy | 1 | 2007 | 1388 | 0.040 |
Why?
|
| Endoscopy | 2 | 2001 | 1834 | 0.040 |
Why?
|
| Species Specificity | 4 | 1995 | 2417 | 0.040 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2021 | 590 | 0.040 |
Why?
|
| Interleukin-1 | 2 | 1996 | 1249 | 0.040 |
Why?
|
| Risk Factors | 8 | 2017 | 73809 | 0.040 |
Why?
|
| Respiratory Physiological Phenomena | 1 | 1999 | 188 | 0.040 |
Why?
|
| Data Interpretation, Statistical | 1 | 2009 | 2690 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2001 | 778 | 0.040 |
Why?
|
| Administration, Cutaneous | 1 | 2001 | 712 | 0.040 |
Why?
|
| Lymph Node Excision | 2 | 2001 | 1303 | 0.040 |
Why?
|
| Virus Latency | 1 | 2001 | 362 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2011 | 4567 | 0.040 |
Why?
|
| Respiratory Tract Diseases | 1 | 2024 | 747 | 0.040 |
Why?
|
| Melanoma | 4 | 2003 | 5691 | 0.040 |
Why?
|
| Antibodies | 1 | 2006 | 2420 | 0.040 |
Why?
|
| Mechanical Phenomena | 1 | 2019 | 140 | 0.040 |
Why?
|
| Exercise Tolerance | 1 | 2003 | 830 | 0.040 |
Why?
|
| Culture Media | 2 | 1992 | 899 | 0.040 |
Why?
|
| Neoplasm Metastasis | 4 | 2009 | 4901 | 0.040 |
Why?
|
| Thermodynamics | 1 | 2019 | 595 | 0.040 |
Why?
|
| Barrett Esophagus | 1 | 2001 | 490 | 0.040 |
Why?
|
| Cisplatin | 4 | 2016 | 1645 | 0.040 |
Why?
|
| Respiratory Sounds | 1 | 2021 | 697 | 0.040 |
Why?
|
| von Willebrand Factor | 1 | 2021 | 672 | 0.040 |
Why?
|
| Muscles | 1 | 1982 | 1579 | 0.040 |
Why?
|
| Radiation Pneumonitis | 1 | 1998 | 102 | 0.040 |
Why?
|
| Disease-Free Survival | 4 | 2016 | 6821 | 0.030 |
Why?
|
| Drug Administration Schedule | 2 | 2016 | 4839 | 0.030 |
Why?
|
| Intestine, Small | 1 | 2023 | 1207 | 0.030 |
Why?
|
| Eosinophils | 2 | 1998 | 946 | 0.030 |
Why?
|
| Pleural Effusion, Malignant | 1 | 1997 | 103 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2006 | 6354 | 0.030 |
Why?
|
| Microscopy, Electron | 1 | 2000 | 2557 | 0.030 |
Why?
|
| Autopsy | 1 | 2020 | 1003 | 0.030 |
Why?
|
| Sarcoidosis, Pulmonary | 1 | 1996 | 45 | 0.030 |
Why?
|
| Surface Properties | 1 | 2019 | 1159 | 0.030 |
Why?
|
| Pulmonary Artery | 2 | 2017 | 1915 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2004 | 2825 | 0.030 |
Why?
|
| Bleomycin | 1 | 2017 | 495 | 0.030 |
Why?
|
| Fiber Optic Technology | 1 | 1997 | 289 | 0.030 |
Why?
|
| Cytokines | 2 | 2009 | 7338 | 0.030 |
Why?
|
| Anorexia | 1 | 2016 | 154 | 0.030 |
Why?
|
| Drug Therapy, Combination | 2 | 2006 | 6293 | 0.030 |
Why?
|
| Vincristine | 1 | 1998 | 1038 | 0.030 |
Why?
|
| Videotape Recording | 1 | 1997 | 337 | 0.030 |
Why?
|
| Laryngeal Masks | 1 | 1996 | 101 | 0.030 |
Why?
|
| Mammals | 1 | 2001 | 1132 | 0.030 |
Why?
|
| Neoplasms | 5 | 1997 | 22032 | 0.030 |
Why?
|
| HLA-B7 Antigen | 4 | 1990 | 50 | 0.030 |
Why?
|
| Ultrasonography | 2 | 2006 | 5952 | 0.030 |
Why?
|
| Fibrosis | 1 | 2022 | 2038 | 0.030 |
Why?
|
| Galactosides | 1 | 1995 | 54 | 0.030 |
Why?
|
| Empyema | 1 | 1995 | 41 | 0.030 |
Why?
|
| Neoplasm Regression, Spontaneous | 1 | 1995 | 46 | 0.030 |
Why?
|
| Pregnancy | 1 | 2017 | 29742 | 0.030 |
Why?
|
| Goats | 1 | 1995 | 167 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2001 | 4023 | 0.030 |
Why?
|
| Airway Remodeling | 1 | 2016 | 134 | 0.030 |
Why?
|
| Phosphatidylethanolamines | 1 | 1995 | 129 | 0.030 |
Why?
|
| Nitroprusside | 1 | 1995 | 272 | 0.030 |
Why?
|
| Cell Transformation, Viral | 1 | 1996 | 526 | 0.030 |
Why?
|
| Cyclophosphamide | 2 | 1998 | 2218 | 0.030 |
Why?
|
| Respiratory Muscles | 2 | 2007 | 142 | 0.030 |
Why?
|
| Attitude | 1 | 1979 | 777 | 0.030 |
Why?
|
| Microchemistry | 1 | 1994 | 54 | 0.030 |
Why?
|
| Lymphatic Diseases | 1 | 1996 | 319 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 7403 | 0.030 |
Why?
|
| Leukemia | 1 | 2003 | 1519 | 0.030 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 1994 | 200 | 0.030 |
Why?
|
| Genes, MHC Class I | 1 | 1995 | 240 | 0.030 |
Why?
|
| Carbohydrate Sequence | 1 | 1994 | 410 | 0.030 |
Why?
|
| Surgical Flaps | 1 | 2003 | 1669 | 0.030 |
Why?
|
| Esophagogastric Junction | 1 | 2016 | 341 | 0.030 |
Why?
|
| Drug Synergism | 1 | 1998 | 1745 | 0.030 |
Why?
|
| Incidence | 5 | 2020 | 21272 | 0.030 |
Why?
|
| Drug Stability | 1 | 1994 | 290 | 0.030 |
Why?
|
| Necrosis | 1 | 1998 | 1604 | 0.030 |
Why?
|
| Cell Division | 1 | 2001 | 4458 | 0.030 |
Why?
|
| Vagotomy, Truncal | 1 | 1993 | 9 | 0.030 |
Why?
|
| Polymers | 1 | 2001 | 1616 | 0.030 |
Why?
|
| Papain | 2 | 2005 | 65 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 2003 | 2414 | 0.030 |
Why?
|
| Peptic Ulcer Perforation | 1 | 1993 | 22 | 0.030 |
Why?
|
| Solutions | 1 | 1994 | 412 | 0.030 |
Why?
|
| Chromatography, Affinity | 1 | 1994 | 534 | 0.030 |
Why?
|
| Prednisone | 1 | 1998 | 1565 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 1998 | 1829 | 0.030 |
Why?
|
| Adolescent | 11 | 2020 | 87892 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 10748 | 0.030 |
Why?
|
| Soft Tissue Neoplasms | 1 | 1982 | 1152 | 0.030 |
Why?
|
| Duodenal Ulcer | 1 | 1993 | 121 | 0.030 |
Why?
|
| Nausea | 1 | 2016 | 677 | 0.030 |
Why?
|
| Avidin | 1 | 1993 | 42 | 0.030 |
Why?
|
| Statistics, Nonparametric | 2 | 2011 | 2850 | 0.030 |
Why?
|
| Acute Kidney Injury | 1 | 1985 | 1926 | 0.030 |
Why?
|
| Fibroblasts | 3 | 2016 | 4087 | 0.030 |
Why?
|
| Vital Capacity | 3 | 2002 | 962 | 0.030 |
Why?
|
| Biopsy | 2 | 2022 | 6768 | 0.030 |
Why?
|
| Hexuronic Acids | 1 | 1992 | 145 | 0.030 |
Why?
|
| Hemodynamics | 1 | 2003 | 4159 | 0.030 |
Why?
|
| Camptothecin | 1 | 2016 | 588 | 0.030 |
Why?
|
| Glucuronic Acid | 1 | 1992 | 150 | 0.030 |
Why?
|
| Amines | 1 | 1994 | 281 | 0.030 |
Why?
|
| Immunologic Techniques | 1 | 1993 | 213 | 0.030 |
Why?
|
| Cholesterol | 1 | 2002 | 2902 | 0.030 |
Why?
|
| Disease Progression | 3 | 2005 | 13468 | 0.030 |
Why?
|
| Antibody Specificity | 1 | 1994 | 1060 | 0.030 |
Why?
|
| Predictive Value of Tests | 5 | 2005 | 15225 | 0.030 |
Why?
|
| Cell Culture Techniques | 1 | 2000 | 1664 | 0.030 |
Why?
|
| Angiography | 1 | 2017 | 1599 | 0.020 |
Why?
|
| Spectrometry, Fluorescence | 1 | 1994 | 681 | 0.020 |
Why?
|
| Artificial Intelligence | 1 | 2006 | 2551 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2006 | 5070 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 1992 | 373 | 0.020 |
Why?
|
| Patient Advocacy | 1 | 1994 | 360 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 1994 | 1705 | 0.020 |
Why?
|
| Respiratory Insufficiency | 1 | 2020 | 1230 | 0.020 |
Why?
|
| Antigen-Antibody Reactions | 1 | 2011 | 346 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 1996 | 4342 | 0.020 |
Why?
|
| Reoperation | 3 | 2001 | 4282 | 0.020 |
Why?
|
| Reproducibility of Results | 3 | 2017 | 20055 | 0.020 |
Why?
|
| Liposomes | 1 | 1995 | 777 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2021 | 3208 | 0.020 |
Why?
|
| Granulation Tissue | 1 | 2011 | 92 | 0.020 |
Why?
|
| HLA-D Antigens | 2 | 1988 | 134 | 0.020 |
Why?
|
| Temperature | 2 | 1989 | 2219 | 0.020 |
Why?
|
| Alginates | 1 | 1992 | 248 | 0.020 |
Why?
|
| Occlusive Dressings | 1 | 2011 | 52 | 0.020 |
Why?
|
| Perfusion | 1 | 1996 | 1374 | 0.020 |
Why?
|
| Radiotherapy | 1 | 1998 | 1504 | 0.020 |
Why?
|
| Receptors, Leukocyte-Adhesion | 1 | 1990 | 52 | 0.020 |
Why?
|
| Interleukin-2 | 2 | 1988 | 1888 | 0.020 |
Why?
|
| Health Priorities | 1 | 1994 | 375 | 0.020 |
Why?
|
| Cytological Techniques | 1 | 1992 | 218 | 0.020 |
Why?
|
| Immunoglobulin A | 1 | 1994 | 979 | 0.020 |
Why?
|
| Lipids | 1 | 2002 | 3326 | 0.020 |
Why?
|
| Immunoglobulin G | 2 | 1994 | 4540 | 0.020 |
Why?
|
| Health Care Rationing | 1 | 1994 | 434 | 0.020 |
Why?
|
| Deglutition Disorders | 1 | 2016 | 625 | 0.020 |
Why?
|
| Cells | 1 | 2011 | 164 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 1992 | 1628 | 0.020 |
Why?
|
| Kidney Transplantation | 1 | 1985 | 4217 | 0.020 |
Why?
|
| Hypersensitivity, Delayed | 2 | 2003 | 490 | 0.020 |
Why?
|
| Immunoglobulin Fab Fragments | 2 | 1989 | 444 | 0.020 |
Why?
|
| Maximal Expiratory Flow-Volume Curves | 2 | 1999 | 25 | 0.020 |
Why?
|
| Genetic Engineering | 3 | 2003 | 933 | 0.020 |
Why?
|
| Disabled Persons | 1 | 1979 | 1224 | 0.020 |
Why?
|
| Haplotypes | 1 | 1996 | 2764 | 0.020 |
Why?
|
| Child, Preschool | 4 | 2022 | 42062 | 0.020 |
Why?
|
| Proportional Hazards Models | 2 | 2007 | 12440 | 0.020 |
Why?
|
| Sex Distribution | 2 | 2005 | 2284 | 0.020 |
Why?
|
| Safety | 3 | 1999 | 1147 | 0.020 |
Why?
|
| Treatment Failure | 3 | 2005 | 2640 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 2 | 1996 | 3617 | 0.020 |
Why?
|
| Radiography | 2 | 2007 | 6954 | 0.020 |
Why?
|
| DNA, Viral | 1 | 1996 | 2194 | 0.020 |
Why?
|
| Immunoglobulin M | 1 | 1994 | 1529 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2017 | 36284 | 0.020 |
Why?
|
| Antigens, Bacterial | 1 | 1995 | 1155 | 0.020 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 1990 | 282 | 0.020 |
Why?
|
| Length of Stay | 5 | 2007 | 6439 | 0.020 |
Why?
|
| Influenza, Human | 1 | 2020 | 1516 | 0.020 |
Why?
|
| Age Distribution | 2 | 2005 | 2882 | 0.020 |
Why?
|
| Multivariate Analysis | 4 | 2005 | 12096 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2001 | 4353 | 0.020 |
Why?
|
| Solubility | 1 | 1990 | 1088 | 0.020 |
Why?
|
| Collagen | 1 | 2017 | 2635 | 0.020 |
Why?
|
| Colony-Stimulating Factors | 1 | 1988 | 218 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2016 | 3991 | 0.020 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2003 | 3216 | 0.020 |
Why?
|
| Smoking | 3 | 1999 | 9051 | 0.020 |
Why?
|
| Splenic Neoplasms | 1 | 1988 | 94 | 0.020 |
Why?
|
| Abdomen | 2 | 2001 | 1129 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2001 | 4549 | 0.020 |
Why?
|
| Gene Rearrangement | 1 | 1992 | 1122 | 0.020 |
Why?
|
| Barium | 1 | 2007 | 62 | 0.020 |
Why?
|
| Delayed Graft Function | 1 | 2007 | 49 | 0.020 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 1990 | 545 | 0.020 |
Why?
|
| Culture Media, Serum-Free | 1 | 2007 | 148 | 0.020 |
Why?
|
| Isomerism | 1 | 2007 | 197 | 0.020 |
Why?
|
| Random Allocation | 1 | 2011 | 2385 | 0.020 |
Why?
|
| Receptors, Interleukin-2 | 1 | 1988 | 562 | 0.020 |
Why?
|
| Proteins | 1 | 2002 | 6026 | 0.020 |
Why?
|
| Karnofsky Performance Status | 2 | 1998 | 165 | 0.020 |
Why?
|
| Wiskott-Aldrich Syndrome | 1 | 1987 | 130 | 0.020 |
Why?
|
| Graft Rejection | 1 | 2000 | 4426 | 0.020 |
Why?
|
| Leukemia, Experimental | 1 | 1986 | 225 | 0.020 |
Why?
|
| Young Adult | 3 | 2020 | 58808 | 0.020 |
Why?
|
| Cytomegalovirus Infections | 2 | 2000 | 831 | 0.020 |
Why?
|
| Transplantation, Autologous | 2 | 2003 | 2114 | 0.020 |
Why?
|
| Agranulocytosis | 1 | 1986 | 99 | 0.020 |
Why?
|
| Arrhythmias, Cardiac | 1 | 1996 | 2248 | 0.020 |
Why?
|
| Pulmonary Veins | 1 | 1992 | 745 | 0.020 |
Why?
|
| Chronic Disease | 2 | 2017 | 9267 | 0.020 |
Why?
|
| Infant | 2 | 2022 | 36055 | 0.020 |
Why?
|
| Prospective Studies | 8 | 2013 | 54137 | 0.020 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2007 | 268 | 0.020 |
Why?
|
| Fluorescein | 1 | 1986 | 174 | 0.020 |
Why?
|
| Linear Models | 3 | 2001 | 5862 | 0.020 |
Why?
|
| Hematocrit | 1 | 1987 | 627 | 0.020 |
Why?
|
| Antigen-Antibody Complex | 1 | 1987 | 513 | 0.020 |
Why?
|
| Lymphocyte Depletion | 1 | 1987 | 602 | 0.020 |
Why?
|
| Kinetics | 3 | 2007 | 6371 | 0.020 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 1985 | 365 | 0.020 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2007 | 553 | 0.020 |
Why?
|
| Breast Neoplasms | 2 | 1996 | 21017 | 0.020 |
Why?
|
| Manometry | 1 | 2007 | 453 | 0.020 |
Why?
|
| Diagnosis, Differential | 2 | 1999 | 12951 | 0.020 |
Why?
|
| Penis | 1 | 1986 | 213 | 0.020 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 1988 | 329 | 0.020 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2007 | 380 | 0.010 |
Why?
|
| Analysis of Variance | 2 | 2005 | 6234 | 0.010 |
Why?
|
| Child | 4 | 2022 | 79818 | 0.010 |
Why?
|
| Vaccination | 1 | 1997 | 3355 | 0.010 |
Why?
|
| Macromolecular Substances | 1 | 1987 | 1433 | 0.010 |
Why?
|
| Tissue Donors | 1 | 1994 | 2311 | 0.010 |
Why?
|
| Collagen Type I | 1 | 2007 | 616 | 0.010 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 2 | 1986 | 973 | 0.010 |
Why?
|
| Clinical Trials as Topic | 2 | 2001 | 7985 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 2005 | 8981 | 0.010 |
Why?
|
| Home Care Services, Hospital-Based | 1 | 2003 | 45 | 0.010 |
Why?
|
| Residual Volume | 1 | 2002 | 41 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 1987 | 2262 | 0.010 |
Why?
|
| Rhabdomyosarcoma | 2 | 1984 | 358 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2007 | 1245 | 0.010 |
Why?
|
| SEER Program | 1 | 2007 | 1530 | 0.010 |
Why?
|
| Histiocytoma, Benign Fibrous | 1 | 1982 | 64 | 0.010 |
Why?
|
| Methods | 1 | 1982 | 1074 | 0.010 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 1985 | 557 | 0.010 |
Why?
|
| Immunosuppressive Agents | 2 | 2000 | 4158 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1994 | 17617 | 0.010 |
Why?
|
| Jejunostomy | 1 | 2001 | 59 | 0.010 |
Why?
|
| Technetium Tc 99m Aggregated Albumin | 1 | 2001 | 66 | 0.010 |
Why?
|
| Esophageal Fistula | 1 | 2001 | 60 | 0.010 |
Why?
|
| Health Policy | 1 | 1994 | 2677 | 0.010 |
Why?
|
| Ventilation-Perfusion Ratio | 1 | 2001 | 117 | 0.010 |
Why?
|
| Esophagus | 1 | 2007 | 1023 | 0.010 |
Why?
|
| Neutrophils | 1 | 1993 | 3765 | 0.010 |
Why?
|
| Sarcoma, Synovial | 1 | 1982 | 151 | 0.010 |
Why?
|
| Neutropenia | 1 | 1986 | 884 | 0.010 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 1988 | 951 | 0.010 |
Why?
|
| Least-Squares Analysis | 1 | 2001 | 369 | 0.010 |
Why?
|
| Physician-Patient Relations | 1 | 1994 | 3242 | 0.010 |
Why?
|
| Normal Distribution | 1 | 2001 | 272 | 0.010 |
Why?
|
| Inspiratory Capacity | 1 | 1999 | 35 | 0.010 |
Why?
|
| Dilatation | 1 | 2001 | 307 | 0.010 |
Why?
|
| Decision Trees | 1 | 2002 | 504 | 0.010 |
Why?
|
| RNA, Viral | 1 | 1988 | 2836 | 0.010 |
Why?
|
| Retinal Vessels | 1 | 2005 | 836 | 0.010 |
Why?
|
| Asthma | 1 | 1998 | 6172 | 0.010 |
Why?
|
| Plethysmography | 1 | 1999 | 174 | 0.010 |
Why?
|
| Adenoviridae | 1 | 2003 | 1084 | 0.010 |
Why?
|
| Catheterization | 1 | 1984 | 1426 | 0.010 |
Why?
|
| Pressure | 1 | 2002 | 1155 | 0.010 |
Why?
|
| Tumor Virus Infections | 1 | 1982 | 438 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2004 | 1630 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2013 | 12262 | 0.010 |
Why?
|
| Equipment Design | 1 | 2007 | 3507 | 0.010 |
Why?
|
| Probability | 1 | 2004 | 2467 | 0.010 |
Why?
|
| Radiotherapy, High-Energy | 1 | 1999 | 228 | 0.010 |
Why?
|
| Phosphoproteins | 1 | 2007 | 2433 | 0.010 |
Why?
|
| Autoantibodies | 1 | 1987 | 2118 | 0.010 |
Why?
|
| Research Design | 1 | 1994 | 6157 | 0.010 |
Why?
|
| Databases as Topic | 1 | 1999 | 472 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 1986 | 4624 | 0.010 |
Why?
|
| Self Care | 1 | 2003 | 794 | 0.010 |
Why?
|
| Muscle Contraction | 1 | 2002 | 1197 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2002 | 1632 | 0.010 |
Why?
|
| Bronchitis | 1 | 1998 | 196 | 0.010 |
Why?
|
| Esophagoscopy | 1 | 1999 | 390 | 0.010 |
Why?
|
| Sclerosing Solutions | 1 | 1997 | 79 | 0.010 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 1 | 1998 | 113 | 0.010 |
Why?
|
| Chromosome Aberrations | 2 | 1995 | 1763 | 0.010 |
Why?
|
| Fluoroscopy | 1 | 2001 | 944 | 0.010 |
Why?
|
| Quality of Life | 1 | 1999 | 13285 | 0.010 |
Why?
|
| Pericardial Window Techniques | 1 | 1996 | 10 | 0.010 |
Why?
|
| Molecular Biology | 1 | 2001 | 580 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 2001 | 1975 | 0.010 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 1999 | 277 | 0.010 |
Why?
|
| Neoplasms, Experimental | 1 | 1982 | 1228 | 0.010 |
Why?
|
| Antidotes | 1 | 1997 | 137 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2003 | 3801 | 0.010 |
Why?
|
| Exercise Therapy | 1 | 2003 | 919 | 0.010 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2001 | 494 | 0.010 |
Why?
|
| Bone Marrow | 1 | 1986 | 2909 | 0.010 |
Why?
|
| Leucovorin | 1 | 1997 | 641 | 0.010 |
Why?
|
| Chromosome Banding | 1 | 1995 | 260 | 0.010 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2002 | 1722 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2007 | 3609 | 0.010 |
Why?
|
| Longitudinal Studies | 2 | 2001 | 14490 | 0.010 |
Why?
|
| Pleural Diseases | 1 | 1995 | 137 | 0.010 |
Why?
|
| Mutation | 2 | 1989 | 29915 | 0.010 |
Why?
|
| ROC Curve | 1 | 2002 | 3563 | 0.010 |
Why?
|
| Choice Behavior | 1 | 1979 | 821 | 0.010 |
Why?
|
| Disease Management | 1 | 2004 | 2500 | 0.010 |
Why?
|
| Health Status Indicators | 1 | 1999 | 970 | 0.010 |
Why?
|
| Pyloric Antrum | 1 | 1993 | 66 | 0.010 |
Why?
|
| Cohort Studies | 3 | 2004 | 41256 | 0.010 |
Why?
|
| Risk Assessment | 2 | 2005 | 23884 | 0.010 |
Why?
|
| Leukemia, T-Cell | 1 | 1993 | 101 | 0.010 |
Why?
|
| Lipoma | 1 | 1995 | 292 | 0.010 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 1998 | 1086 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 1992 | 26183 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 1992 | 246 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 1992 | 286 | 0.010 |
Why?
|
| Drainage | 1 | 1997 | 1161 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 1992 | 410 | 0.010 |
Why?
|
| Boston | 1 | 2004 | 9304 | 0.010 |
Why?
|
| Sepsis | 1 | 1985 | 2587 | 0.010 |
Why?
|
| Cell Hypoxia | 1 | 1993 | 655 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 2001 | 2634 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 1992 | 430 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 1999 | 4809 | 0.010 |
Why?
|
| Age Factors | 2 | 1999 | 18358 | 0.010 |
Why?
|
| Protein Conformation | 2 | 1989 | 3966 | 0.010 |
Why?
|
| Karyotyping | 1 | 1992 | 1171 | 0.010 |
Why?
|
| Pain | 1 | 1986 | 5065 | 0.010 |
Why?
|
| Morbidity | 1 | 1996 | 1754 | 0.010 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 1993 | 691 | 0.010 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 1990 | 176 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 1997 | 2359 | 0.010 |
Why?
|
| Leiomyoma | 1 | 1995 | 654 | 0.010 |
Why?
|
| Motivation | 1 | 1979 | 1996 | 0.010 |
Why?
|
| Carcinoma | 1 | 2001 | 2330 | 0.010 |
Why?
|
| Protein Binding | 1 | 2002 | 9311 | 0.010 |
Why?
|
| Esterases | 1 | 1989 | 97 | 0.010 |
Why?
|
| Attention | 1 | 1979 | 2387 | 0.010 |
Why?
|
| Muromonab-CD3 | 1 | 1989 | 104 | 0.010 |
Why?
|
| Cystic Fibrosis | 1 | 1998 | 1274 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 1984 | 4313 | 0.000 |
Why?
|
| Cost-Benefit Analysis | 1 | 2002 | 5484 | 0.000 |
Why?
|
| Health Care Costs | 1 | 2002 | 3245 | 0.000 |
Why?
|
| Intubation, Intratracheal | 1 | 1996 | 1327 | 0.000 |
Why?
|
| Precipitin Tests | 1 | 1988 | 814 | 0.000 |
Why?
|
| Tunicamycin | 1 | 1987 | 108 | 0.000 |
Why?
|
| Transformation, Genetic | 1 | 1987 | 192 | 0.000 |
Why?
|
| Isoantigens | 1 | 1989 | 552 | 0.000 |
Why?
|
| H-2 Antigens | 1 | 1987 | 358 | 0.000 |
Why?
|
| Signal Transduction | 1 | 1990 | 23342 | 0.000 |
Why?
|
| Translocation, Genetic | 1 | 1992 | 1387 | 0.000 |
Why?
|
| Pericardium | 1 | 1991 | 674 | 0.000 |
Why?
|
| United States | 2 | 2007 | 72136 | 0.000 |
Why?
|
| Aotus trivirgatus | 1 | 1986 | 36 | 0.000 |
Why?
|
| Oxygen Consumption | 1 | 1993 | 1845 | 0.000 |
Why?
|
| Major Histocompatibility Complex | 1 | 1989 | 928 | 0.000 |
Why?
|
| Growth Substances | 1 | 1988 | 768 | 0.000 |
Why?
|
| Uterine Neoplasms | 1 | 1995 | 1439 | 0.000 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 1988 | 629 | 0.000 |
Why?
|
| Receptors, Fc | 1 | 1989 | 534 | 0.000 |
Why?
|
| Exercise Test | 1 | 1993 | 2121 | 0.000 |
Why?
|
| Binding Sites | 1 | 1993 | 6036 | 0.000 |
Why?
|
| Macrophage-1 Antigen | 1 | 1985 | 286 | 0.000 |
Why?
|
| Anxiety | 1 | 1979 | 4539 | 0.000 |
Why?
|
| Glycosylation | 1 | 1987 | 1095 | 0.000 |
Why?
|
| Oligonucleotides | 1 | 1987 | 582 | 0.000 |
Why?
|
| Myocardial Infarction | 1 | 1985 | 11424 | 0.000 |
Why?
|
| Macrophages | 1 | 1998 | 5737 | 0.000 |
Why?
|
| Tampons, Surgical | 1 | 1982 | 10 | 0.000 |
Why?
|
| Moloney murine leukemia virus | 1 | 1982 | 109 | 0.000 |
Why?
|
| Transplantation, Isogeneic | 1 | 1982 | 248 | 0.000 |
Why?
|
| Immunotherapy | 1 | 1997 | 4641 | 0.000 |
Why?
|
| Lipopolysaccharides | 1 | 1988 | 2204 | 0.000 |
Why?
|
| Culture Techniques | 1 | 1980 | 530 | 0.000 |
Why?
|
| Models, Molecular | 1 | 1989 | 5410 | 0.000 |
Why?
|
| Neoplasm Transplantation | 1 | 1982 | 2013 | 0.000 |
Why?
|
| Amino Acid Sequence | 1 | 1987 | 13447 | 0.000 |
Why?
|
| Organ Specificity | 1 | 1980 | 1955 | 0.000 |
Why?
|